Wellington Management Group LLP lessened its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 8.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,739,167 shares of the company's stock after selling 151,482 shares during the period. Wellington Management Group LLP owned approximately 3.16% of LivaNova worth $143,012,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Invesco Ltd. increased its position in LivaNova by 714.7% in the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company's stock worth $46,313,000 after purchasing an additional 902,447 shares during the last quarter. Scopia Capital Management LP purchased a new stake in LivaNova during the second quarter valued at $36,657,000. Millennium Management LLC lifted its position in LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company's stock valued at $155,559,000 after purchasing an additional 544,033 shares during the last quarter. AQR Capital Management LLC lifted its position in LivaNova by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company's stock valued at $132,606,000 after purchasing an additional 496,165 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of LivaNova by 1,978.8% in the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company's stock worth $29,961,000 after buying an additional 448,703 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on LIVN. Zacks Research cut shares of LivaNova from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Stifel Nicolaus set a $85.00 price target on LivaNova in a research report on Wednesday, August 5th. Robert W. Baird reduced their price objective on LivaNova from $78.00 to $76.00 and set an "outperform" rating on the stock in a research note on Thursday, May 7th. Mizuho raised their price objective on LivaNova from $90.00 to $95.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th. Finally, Weiss Ratings upgraded LivaNova from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, August 18th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $83.50.
View Our Latest Report on LIVN
LivaNova Price Performance
Shares of LIVN stock opened at $79.81 on Tuesday. The stock has a 50 day moving average price of $80.64 and a 200 day moving average price of $72.49. LivaNova PLC has a 52-week low of $48.82 and a 52-week high of $85.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The firm has a market capitalization of $4.40 billion, a P/E ratio of 23.61 and a beta of 0.86.
LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. During the same quarter in the prior year, the company posted $1.05 EPS. LivaNova's quarterly revenue was up 10.8% on a year-over-year basis. As a group, sell-side analysts predict that LivaNova PLC will post 3.77 earnings per share for the current year.
LivaNova Company Profile
(
Free Report)
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
